ProCE Banner Activity

Pivotal Phase II Trial of Glofitamab in R/R DLBCL

Slideset Download
Conference Coverage
This pivotal phase II trial of glofitamab in patients with heavily pretreated, refractory DLBCL demonstrated a CR rate of 39.4%, with similar CR rates with or without previous CAR T-cell therapy.

Released: June 05, 2022

Expiration: June 04, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab